ARFXF - ProMIS Neurosciences, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1576
-0.0015 (-0.94%)
At close: 2:52PM EDT
Stock chart is not supported by your current browser
Previous Close0.1591
Open0.1710
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1576 - 0.1710
52 Week Range0.1400 - 0.3400
Volume65,000
Avg. Volume106,358
Market Cap41.891M
Beta (3Y Monthly)-1.40
PE Ratio (TTM)N/A
EPS (TTM)-0.0260
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ProMIS Neurosciences Announces Second Quarter 2019 Results
    PR Newswire

    ProMIS Neurosciences Announces Second Quarter 2019 Results

    TORONTO and CAMBRIDGE, MA, Aug. 13, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and six months ended June 30, 2019. "Over the course of the first half of 2019, the breadth and depth of our unique discovery and development platform was further evidenced as ProMIS made considerable progress in expanding its portfolio of opportunities in neurodegenerative diseases," stated Eugene Williams, ProMIS' Executive Chairman.

  • GlobeNewswire

    ProMIS Neurosciences Announces Results of Annual Meeting of Shareholders

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced the voting results of the Corporation's annual meeting of shareholders held on June 27, 2019 in Toronto, Ontario, Canada (the "Meeting"). ProMIS is pleased to announce that all of the resolutions announced in the Management Proxy Circular and placed before the Meeting were overwhelmingly approved by the shareholders. The total number of common shares represented by shareholders present in person or by proxy at the Meeting was 50,109,185, representing 19.52% of the Corporation's outstanding common shares.

  • ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019
    PR Newswire

    ProMIS Neurosciences Highlights Data for PMN310 at AAIC 2019

    TORONTO and CAMBRIDGE, MA, July 18, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data today for its lead clinical candidate, PMN310 for Alzheimer's disease, at the annual Alzheimer's Association International Conference® (AAIC) in Los Angeles. In an oral presentation, Chief Development Officer Dr. Johanne Kaplan highlighted the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta (AßO), a root cause of Alzheimer's disease.

  • GlobeNewswire

    ProMIS Neurosciences to Present Data at 2019 Alzheimer’s Association International Conference

    TORONTO and CAMBRIDGE, Mass., July 10, 2019 -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of.

  • ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference
    CNW Group

    ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference

    ProMIS Neurosciences to Present Data at 2019 Alzheimer's Association International Conference

  • ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports
    CNW Group

    ProMIS Neurosciences' Data for Alzheimer's Disease Clinical Candidate PMN310 Published in Scientific Reports

    TORONTO and CAMBRIDGE, MA , July 9, 2019 /CNW/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that supporting data for PMN310, its lead antibody candidate for Alzheimer's disease (AD), have been published in Scientific Reports, a journal of the Nature Research family. The open-access study is available on the Scientific Reports website using the following direct link: https://rdcu.be/bJeLB.

  • GlobeNewswire

    ProMIS Neurosciences’ Data for Alzheimer’s Disease Clinical Candidate PMN310 Published in Scientific Reports

    TORONTO and CAMBRIDGE, Mass., July 09, 2019 -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of.

  • GlobeNewswire

    ProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, presented data for its lead program, PMN310 for Alzheimer’s disease, at last week’s Keystone Symposium on Neurodegenerative Diseases. ProMIS’ Chief Development Officer Dr. Johanne Kaplan presented data showing that PMN310 possesses superior selectivity for amyloid beta toxic oligomers (AßOs) and improved therapeutic potential compared with other Aß-directed antibodies.

  • ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
    CNW Group

    ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

    ProMIS Neurosciences' PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies

  • GlobeNewswire

    ProMIS Neurosciences Closing Private Placement

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that it is closing today a private placement of 4,680,000 units (the “Units”) at a price of CDN$0.25 (or US$0.1875) per Unit (the “Offering Price”) for gross proceeds of approximately CDN$1,170,000 (the “Offering”). “We are pleased with the completion of this private placement”, stated Dr. Elliot Goldstein, ProMIS President and CEO. Each Unit consists of one common share of the Company (each a “Share”) and one share purchase warrant of the Company (each a “Warrant”).

  • ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
    CNW Group

    ProMIS Neurosciences Appoints Renowned Parkinson's Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board

    TORONTO and CAMBRIDGE, MA , June 19, 2019 /CNW/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, welcomed Warren Olanow , MD, FRCPC, FAAN, FRCP(Hon) to its scientific advisory board (SAB). Dr. Olanow has dedicated his career to the study of neurodegeneration, particularly Parkinson's disease, through his award-winning work in academia, scientific research, clinical trials and professional societies.

  • GlobeNewswire

    ProMIS Neurosciences Appoints Renowned Parkinson’s Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, welcomed Warren Olanow, MD, FRCPC, FAAN, FRCP (Hon) to its scientific advisory board (SAB). Dr. Olanow has dedicated his career to the study of neurodegeneration, particularly Parkinson’s disease, through his award-winning work in academia, scientific research, clinical trials and professional societies.

  • ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference
    CNW Group

    ProMIS Neurosciences Presents Lead Program for Alzheimer's Disease at Prestigious Keystone Symposia Scientific Conference

    TORONTO and CAMBRIDGE, MA , June 5, 2019 /CNW/ - ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present key data on monoclonal antibody PMN310 for Alzheimer's disease at the Keystone Symposium on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities. For nearly fifty years, the conference has attracted the world's most accomplished researchers in neurodegenerative diseases to discuss future directions in therapy and care.

  • GlobeNewswire

    ProMIS Neurosciences Presents Lead Program for Alzheimer’s Disease at Prestigious Keystone Symposia Scientific Conference

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will present key data on monoclonal antibody PMN310 for Alzheimer’s disease at the Keystone Symposium on Neurodegenerative Diseases: New Insights and Therapeutic Opportunities. For nearly fifty years, the conference has attracted the world’s most accomplished researchers in neurodegenerative diseases to discuss future directions in therapy and care.